自身抗体在皮肌炎患者管理中的应用

Application of autoantibodies in management of dermatomyositis patients

皮肌炎(DM)是一种特发性炎性肌病(IIMs),患者通常伴有关节炎、心肌病、间质性肺病(ILD)和恶性肿瘤的肌肉外表现。ILD和伴随的恶性肿瘤是导致DM患者死亡的主要原因。由于患者的临床特征、治疗反应和预后差异很大,因此在开始治疗前预测DM患者的预后至关重要。肌炎特异性自身抗体(MSAs)和肌炎相关自身抗体(MAAs)不仅可用于诊断,而且对预测DM患者的临床特征、对治疗的反应和预后也很有用,有助于在常规临床实践中更好地管理皮肌炎患者。本综述描述了如何将自身抗体结果纳入DM患者的临床实践中,主要是成人患者。

Dermatomyositis(DM)is an idiopathic inflammatory myopathy(IIM).DM patients are usually accompanied by extramuscular manifestations such as arthritis,cardiomyopathy,interstitial lung disease(ILD),and malignant tumors.ILD and associated malignant tumors are the main causes of death in DM patients.Because the clinical characteristics,treatment response,and prognosis of DM patients are very different,it is very important to predict the prognosis of DM patients before treatment.Myositis specific autoantibodies(MSAs)and myositis associated autoantibodies(MAAs)can not only be used for diagnosis,but they are also useful for predicting the clinical characteristics,response to treatment,and prognosis of DM patients,which is helpful to better manage DM patients in routine clinical practice.This review describes how to incorporate autoantibody results into clinical practice in patients with DM,mainly adult patients.